69 results about "Lymphocytic leukaemia" patented technology

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38+ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and / or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CD38 protein.

Compounds of the present invention, alone and in combination with other active agents, find utility in the treatment of hyperproliferative diseases, mammalian cancers and especially human cancers including but not limited to for example malignant melanomas, myeloproliferative diseases, chronic myelogenous leukemia, acute lymphocytic leukemia, a disease caused by c-ABL kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof.

The invention relates to a tumour necrosis factor- (TNF-) related apoptosis-inducing ligand (TRAIL) which is capable of selectively signalling through death receptor 4 (DR4), comprising Y at position 189. Preferably the TRAIL further comprises 19 IL and / or 199V; preferably also 201R, 213W and 215D, and / or preferably further comprises 193S. The invention also relates to uses of such TRAIL mutants which are capable of selectively signalling through DR4 in the treatment of cancer, and in the manufacture of medicaments for use in treatment of cancer. Preferably the cancer is chronic lymphocytic leukaemia, mantle cell lymphoma or non-Hodgkin's lymphoma. The invention also relates to kits comprising same.

The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions comprising a humanized monoclonal antibody recognizing the leukocyte differentiation antigen CD6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions comprising a humanized anti-CD6 monoclonal antibody for the diagnosis and treatment of Lymphoproliferative Syndromes and particularly the B-Cell Chronic Lymphocytic Leukemia. The essence of the invention consist in the application of a humanized Monoclonal Antibody that recognizes the CD6 antigen, the generation of pharmaceutical compositions comprising that antibody being able to induce apoptosis of malignant cells from B-Cell Chronic Lymphocytic Leukemia patients, reaching a clinical and a histological antitumor efficacy. The field of application of the present invention extends to the Oncology.

The disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a purine analog for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia.

The invention relates to tubulin depolymerizing agent polypeptides and application thereof, particularly polypeptides capable of inhibiting polymerization of tubulin and treating acute lymphatic leukemia. The invention is characterized in that the sequence of the tubulin depolymerizing agent polypeptides 1 is CRALERLV disclosed as SEQ NO.1. The invention also relates to application of the tubulin depolymerizing agent polypeptides 1 in preparation of medicines for treating acute lymphatic leukemia. A solid-phase synthesis method is utilized to chemically synthesize the tubulin depolymerizing agent polypeptides 1; and the polypeptides with the bran-new sequence can inhibit tubulin in vitro and treat acute lymphatic leukemia.

The present invention relates to ligands of HVEM for the treatment of hematologic malignancies, in particular Chronic lymphocytic leukaemia, and for the treatment of autoimmune diseases.

The present invention provides methods for establishing a composite marker profile for a sample derived from an individual suspected having a neoplastic condition. A composite marker profile of the invention allows for identification of prognostically and therapeutically relevant subgroups of neoplastic conditions and prediction of the clinical course of an individual. The methods of the invention provide tools useful in choosing a therapy for an individual afflicted with a neoplastic condition, including methods for assigning a risk group, methods of predicting an increased risk of relapse, methods of predicting an increased risk of developing secondary complications, methods of choosing a therapy for an individual, methods of determining the efficacy of a therapy in an individual, and methods of determining the prognosis for an individual. In particular, the method of the present invention discloses a method for establishing a composite marker profile that can serve as a prognostic indicator to predict whether the course of a neoplastic condition in a individual will be aggressive or indolent, thereby aiding the clinician in managing the patient and evaluating the modality of treatment to be used. In particular embodiments disclosed herein, the methods of the invention are directed to establishing a composite marker profile for a leukemia selected from the group consisting of Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Acute Lymphocytic Leukemia (ALL).

The invention discloses a tubulin depolymerizing agent polypeptide and an application thereof, relating to the field of medicines and particularly relating to a polypeptide which has a function of suppressing tubulin polymerization and is used for treating acute lymphocytic leukemia. The sequence of the tubulin depolymerizing agent polypeptide is MFSPSCVSLLRCTGCC which is a brand new sequence; and the tubulin depolymerizing agent polypeptide can suppress the tubulin polymerization in vitro at a 1mmol level and increase the survival rate of tumor-bearing mice during in vivo tests, and has potential values in new medicine development.

The present invention discloses an IRF4 gene polymorphism detection kit through a pyrosequencing method, and a method thereof. With the kit, IRF4 gene polymorphism can be detected, and specifically rs872071 (A is more than G) single nucleotide polymorphism is detected. The kit comprises primers represented by SEQ ID NO.2-4. According to the kit, accurate, fast and high-throughput detection can be performed on the IRF4 gene polymorphism so as to achieve effective prediction and prevention of susceptibility risk of chronic lymphocytic leukaemia.

The present invention discloses a medicine compound for curing leukaemia and cancer, including Chinese ephedra, cinnamon twig, liquorice, largehead atractylode, pachyma cocos and prepared pinellia tuber. The medicine compound provided by the present invention can cure leukaemia, gastric cancer, galactophore cancer and uterus cancer without replacing medulla and operation; the success rate for patients in early and middle stages is up to more than 95 percent; in particular, the present invention has better effect for acute hepatosplenomegaly and lymphocytic leukaemia without any side effect.

The invention relates to the field of medicine, particularly polypeptides with focal adhesion kinase inhibiting activity capable of treating acute lymphatic leukemia. The sequence is ADLIDGYRLVNGTSQRALERLV which is a brand-new sequence; the polypeptides can inhibit focal adhesion kinase activity in vitro, can enhance the survival rate of tumor bearing mice in an in-vivo experiment, and have potential value in developing new drugs.

—use of a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or of a pharmaceutical composition containing same, as a sole active agent, or of a combination of a) said compound or a pharmaceutical composition containing said compound and b) one or more further active agents, for the preparation of a medicament for the treatment or prophylaxis of non-Hodgkin's lymphoma (NHL), particularly 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-Hodgkin's lymphoma (NHL), in particular follicular lymphoma (FL), chronic lymphocytic leukaemia (CLL), marginal zone lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), transformed lymphoma (TL), or peripheral T-cell lymphoma (PTCL); —combinations of a) said compound and b) one or more further active agents; —a pharmaceutical composition comprising said compound as a sole active agent for the treatment of non-Hodgkin's lymphoma (NHL), particularly 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-Hodgkin's lymphoma (NHL), in particular follicular lymphoma (FL), chronic lymphocytic leukaemia (CLL), marginal zone lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), transformed lymphoma (TL), or peripheral T-cell lymphoma (PTCL); —a pharmaceutical composition comprising a combination of a) said compound and b) one or more further active agents; —use of biomarkers involved in the modification of the expression of PI3K isoforms, BTK and IKK, BCR activation, BCR downstream activation of NFKB pathway, c-Myc, EZH2, for predicting the sensitivity and / or resistance of a cancer patient to said compound and providing a rationale-based synergistic combination as defined herein to increase sensitivity and / or to overcome resistance; and —a method of determining the level of a component of one or more of the expression of PI3K isoforms, BTK and IKK, BCR activation, BCR downstream activation of NFKB pathway, c-Myc, EZH2.

The present invention relates to combinations of at least two components, component A and component B, component A being an inhibitor of PI3K kinase, and component B being venetoclax or palbociclib. Another aspect of the present invention relates to the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particurlarly for the treatment or prophylaxis of non-Hodgkin's lymphoma (hereinafter abbreviated to “NHL”), particularly 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-Hodgkin's lymphoma (NHL), in particular follicular lymphoma (hereinafter abbreviated to “FL”), chronic lymphocytic leukaemia (hereinafter abbreviated to “CLL”), marginal zone lymphoma (hereinafter abbreviated to “MZL”), splenic marginal zone lymphoma (hereinafter abbreviated to “SMZL”), diffuse large B-cell lymphoma (hereinafter abbreviated to “DLBCL”), mantle cell lymphoma (MCL), transformed lymphoma (hereinafter abbreviated to “TL”), or peripheral T-cell lymphoma (hereinafter abbreviated to “PTCL”).

The invention relates to the field of medicaments, and in particular relates to a polypeptide which can promote the polymerization of tubulin and treat acute lymphocytic leukemia. The sequence of the polypeptide is EVVPFQEVWGRSYCRA and is a new sequence; the polymerization of the tubulin can be promoted by 1 micromolar level of the polypeptide in vitro, and the survival rate of tumor-bearing mice can be increased in vivo experiments; and therefore, the polypeptide has a potential new medicament development value.

The invention discloses a construction method of an acute lymphocytic leukemia mouse model. The construction method comprises the following steps of preparing leukemia cell line suspension with high expression of ERG, knocking down ERG protein expression of the cell line by using shERG packaged by lentivirus, transfecting Luciferase into a wild type and shERG cell line by lentivirus, inoculating the cell line into an immunodeficient mouse, evaluating the tumor process by using a small animal imaging system, and evaluating the treatment effect of a specific drug on the acute lymphocytic leukemia with high expression of ERG by using the small animal imaging system and a flow analysis method, and the like. The model evaluates the efficacy of a specific drug on a subtype of acute lymphocytic leukemia. According to the disease model construction method provided by the invention, the tumor development process of the model animal can be directly and noninvasively evaluated, and the success rate is very high. In addition, the disease model established according to the method provided by the invention has very high clinical correlation.

The invention discloses an ibrutinib preparation and application thereof. The ibrutinib preparation is prepared from ibrutinib, lactose, microcrystalline cellulose and a pharmaceutically-acceptable carrier, and the ibrutinib preparation with the good flowability, stability and dissolution rate can be obtained, so that the ibrutinib preparation is suitable for large industrial production. The ibrutinib preparation is used for a medicine composition for treating patients suffering from MCL and CLL, the compatibility is reasonable, medicine can be rapidly released, and the good treatment effect on diseases can be generated.

The present invention discloses a medicine compound for curing leukaemia and cancer, including Chinese ephedra, cinnamon twig, liquorice, largehead atractylode, pachyma cocos and prepared pinellia tuber. The medicine compound provided by the present invention can cure leukaemia, gastric cancer, galactophore cancer and uterus cancer without replacing medulla and operation; the success rate for patients in early and middle stages is up to more than 95 percent; in particular, the present invention has better effect for acute hepatosplenomegaly and lymphocytic leukaemia without any side effect.

The present disclosure provides anti-CD19 antibodies and venetoclax for use in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or small lymphocytic lymphoma. The anti-CD19 antibodies, in particular MOR00208, and venetoclax are administered to patients suffering non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and / or small lymphocytic lymphoma (SLL) according to a specific treatment paradigm to mitigate therapy associated tumor lysis syndrome.

Disclosed herein is a bi-specific form of a T cell receptor mimic (TCRm) mAb with reactivity to human immune effector cell antigen and a WT1 peptide / HLA-A epitope. This antibody selectively bound to leukemias and solid tumor cells expressing WT1 and HLA-A as well as activated resting human T cells to release interferon-(IFN-gamma) and to kill the target cancer cells in vitro. Importantly, the antibody mediated autologous T cell proliferation and directed potent cytotoxicity against fresh ovarian cancer cells. Therapeutic activity in vivo of the antibody was demonstrated in NOD SCID SCID Yc*(NSG) mice with three different human cancers expressing WT1 / HLA-A2 including disseminated Ph+ acute lymphocytic leukemia (ALL), disseminated acute myeloid leukemia, and peritoneal mesothelioma. In both of the leukemia xenograft models, mice that received the antibody and T cells also showed longer survival and delayed limb paralysis. Also provided are methods for stimulating a primary T cell response comprising stimulating cytotoxic T cells against a first tumor antigen and a secondary T cell response comprising stimulating effector T cells and / or memory T cells against a first tumor antigen and / or against a second tumor antigen using the bi-specific antibodies described herein.

The invention relates to the field of medicine, particularly polypeptides with focal adhesion kinase inhibiting activity capable of treating acute lymphatic leukemia. The sequence is DGSLLEEITKMQISE which is a brand-new sequence; the polypeptides can inhibit focal adhesion kinase activity in vitro, can enhance the survival rate of tumor bearing mice in an in-vivo experiment, and have potential value in developing new drugs.

The present invention provides methods and compositions for screening, diagnosis and prognosis of colorectal cancer, kidney cancer, liver cancer, lung cancer, lymphoid leukaemia (particularly chronic lymphocytic leukaemia), ovarian cancer or pancreatic cancer, for monitoring the effectiveness of colorectal cancer, kidney cancer, liver cancer, lung cancer, lymphoid leukaemia (particularly chronic lymphocytic leukaemia), ovarian cancer or pancreatic cancer treatment, and for drug development.

The invention relates to the field of medicines, and concretely relates to a polypeptide having focal adhesion kinase inhibition activity and capable of treating acute lymphocytic leukemia. The sequence of the polypeptide is EAIEAYMQDDDGD which is a brand new sequence, and the polypeptide can inhibit the focal adhesion kinase activity in vitro, can improve the survival rate of tumor-bearing mice in in-vivo tests, and has potential new drug exploitation values.

The invention relates to the field of medicines, and concretely relates to a polypeptide having matrix metalloprotease-2 inhibition activity and capable of treating acute lymphocytic leukemia. The polypeptide is modified by polyethylene glycol, the sequence of the polypeptide is mPEG-SC10k-PRO-THR-THR-ASN-ARG which is a brand new sequence, and the polypeptide can inhibit the activity of the matrix metalloprotease-2 in vitro, can improve the survival rate of tumor-bearing mice in in-vivo tests, and has potential new drug exploitation values.

The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a BCL-2 inhibitor for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia.

The invention relates to the field of medicine, particularly polypeptides capable of inhibiting polymerization of tubulin and treating acute lymphatic leukemia. The sequence is CRALERLV which is a brand-new sequence. The polypeptides can inhibit polymerization of tubulin in vitro on the 1 micromole level and enhance the survival rate of tumor bearing mice in an in-vivo test, thereby having potential new drug development value.